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Aim: To study the correcting effects of microgranulated HSGD enterosorbent on hematological, morphological and biochemical 
indices of paraneoplastic syndrome in mice with highly angiogenic variant of Lewis lung carcinoma LLC/R9. Methods: The study 
was performed on male С57/ВL6 mice with transplanted LLC/R9. Enterosorbent HSGD was administered daily at a dose 
of 0.625 g/kg for 2 weeks starting from 7th day after tumor cell transplantation. When enterosorption was completed, an analysis 
of peripheral blood, biochemical indices and morphological structure of tumor, lung, liver, spleen and thymus was carried out 
by standard methods. Results: It has been shown that administration of enterosorbent did not affect LLC/R9 growth but resulted 
in nearly two fold decrease of the volume of lung metastases (p < 0.05). Erythrocyte number and hemoglobin level were higher 
by 30.0% (p < 0.05) and 23.3% (p < 0.05), respectively, in mice treated with enterosorbents as compared to untreated animals. 
In addition sorbent treatment completely normalized the thrombocyte index resulting in elevation of platelet number by 54.5% 
(p < 0.01) up to their level in intact mice. The morphological examination of liver and biochemical analysis of peripheral blood 
evidenced on significant positive correcting effect of enterosorption on histological structure of this organ and its functional acti vity. 
Normalization of total proteins and serum albumin level as well as significant decrease of total lipid concentration by 29% (p < 0.01) 
in blood of treated mice were observed. Conclusion: Positive influence of microgranulated carbon sorbent on some hematological, 
morphological and biochemical indices of tumor associated symptoms in LLC/R9-bearing mice denotes that enterosorption-based 
therapy can be considered as a prospective treatment for correction of some paraneoplastic syndrome signs in cancer patients.
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It is known that malignant tumor due to its sys-
temic influence on an organism is capable to induce 
the development of paraneoplastic syndrome (PNS) 
which encompasses significant metabolic malfunc-
tions, immune conflict between the tumor and a host, 
complex changes in the structure and functions 
of many organs and systems. The phenomenon 
of PNS is mediated by humoral factors of tumor 
origin (hormones, cytokines) or cytokines produced 
by effector cells of antitumor immune response [1, 2].
According to the statistical data, PNS is observed 
in 7–15% of cancer patients and is life treating in many 
cases [3]. Among the most severe malfunctions 
caused by systemic influence of cancer process 
one could mention tumor-associated anemia (TAA) 
which affects approximately 30% of primary cancer 
patients [4] while in the patients treated with chemo-
therapy, its rate achieves 90% [5]. An analysis of TAA 
influence of survival of cancer patients has shown 
that an average annual risk of death is by 65% higher 
in the patients with anemia than in the patients without 
TAA [6]. Lung carcinoma which is characterized by the 
highest PNS incidence among all cancer types, is ac-
companied with TAA in 71% cases [7].
Transfusion of allogeneic red blood cells causes 
quick elevation of hemoglobin level and hematocrit 
and is among known means for anemia correction [8]. 
 However, this approach provides just short-term effect 
and is accompanied with hemolytic reactions, the risk 
of development of many complications, in particular 
heart failure, alloimmunization, disturbed homeosta-
sis and the risk of bacterial contamination and viral 
pathologies [9].
As far as an important factor responsible for ane-
mia development in cancer patients is the relative 
or absolute deficiency of erythropoietin, a key regu-
lator of erythropoiesis, for TAA treatment one could 
use erythropoiesis-stimu lating agents, including the 
preparations of recombinant erythropoietin of first 
generation which possess high efficacy but short-term 
action, and the preparations with prolonged effect. 
However, this approach also is imperfect, because 
after treatment with erythropoiesis-stimula +ting 
agents there is a risk of side effects development such 
as tromboembolic complications affecting total sur-
vival and possible stimulation of cancer process [10]. 
Apart from this the majority of experts consider it rea-
sonable to use erythropoiesis-stimulating agents only 
in patients who underwent chemotherapy excluding 
the ones with myelodysplastic syndrome. Another 
way for TAA correction is based on elevation of ex-
pression of the genes — targets of hypoxia-inducible 
factor-1а (GIF-1а), a key regulator of pathophysi-
ologic response toward hypoxia, in particular, the gene 
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of erythropo ietine using compounds capable to sup-
press  HIF-prolyl-4-hydrolase [11, 12]. However, if one 
accounts the role played by GIF in tumor development, 
the use of GIF inhibitors could be risky.
So, the development of alternative methods for 
TAA correction is still very actual task. Enterosorption 
(ES) could be considered as an active method for cor-
rection of some paraneoplastic symptoms including 
paraneoplastic anemia. As it was shown carbon en-
terosorbents possess special properties which make 
them capable to normalize cytokine profile, endothelial 
dysfunction and some immunological parameters, 
to mitigate the manifestation of myelosupression, 
to elevate functional activity of detoxification systems 
and to improve their morphological parameters and 
regenerative potency [13].
So the main purpose of the work was to study the 
influence of ES on paraneoplastic symptoms in mice 
with highly angiogenic variant of Lewis lung carcinoma 
(LLC/R9), the growth of which is accompanied with 
expressed PNS manifestations, in particular devel-
opment of anemia, thrombopenia, hepatomegaly, 
splenomegaly and thymus involution [14].
LLC/R9 was generated from the wild-type of Lewis 
lung carcinoma (LLC) strain after 9 sequential cis-DDP 
courses in vivo and following adaptation of tumor 
cells in vitro [15]. High angiogenic potential of LLC/
R9 cells as compared to LLC has been evidenced by (і) 
1.5 fold higher rate of VEGF secretion in vitro; (іі) more 
expressed ability to induce vessel growth on chick em-
bryo chorioallantoic membrane; (ііі) higher sensitivity 
to the action of antiangiogenic agents [16–19].
MATERIALS AND METHODS
In the study, male С57/BL6 mice 2–2.5 months old 
weighting 18–23 g (n = 40) bred in the animal facility 
of Institute of Experimental Pathology, Oncology and 
Radiobio logy of the National Academy of Sciences 
of Ukraine (Kyiv, Ukraine) were used. The research 
was performed in accordance with the rules of local 
committee on ethic aspects of work with experimental 
animals.
LLC/R9 cells were cultured in vitro in RPMI medium 
(Sigma, USA) supplemented with 10% fetal calf serum 
(FCS), 2 mM L-glutamine, and 40 mg/ml gentamycine 
at 37 °C in humidified atmosphere with 5% CO2. Tumor 
cells were inoculated intramuscularly (1•106 cells per 
animal in 0.1 ml of Hanks’ solution).
At the next day after transplantation animals were 
randomized by weight, and distributed in 2 groups 
(11 mice per group): control group (without treatment) 
and experimental group (treated with fine fraction 
of granulated HSGD enterosorbent). Enterosorbent 
was administered via tube daily starting from day 
7 after tumor cells inoculation for 2 weeks. Total dose 
of enterosorbent was 0.625 mg/kg of animal’s body 
weight.
Body weight and tumor size for each mouse were 
recorded 3–4 times a week. In a day after the end 
of ES treatment (on 21st day after tumor cell inocu-
lation) mice were sacrificed. The size of metastatic 
nodules and their number on the surface of five lung 
lobules of each mouse were determined using a bin-
ocular with dimension glass.
The volume of primary tumor (Vi mm3) and total 
volume of lung metastases (Vm mm3) for each mouse 
were calculated using the following formulas:
Vi = π • di3/6;
Vm = π • [Σ
j
 nj • dm3(j)]/6;
dm(j) = 0,5 • j;
j = 1...10,
where di — linear size (mm) of the tumor; nj — num-
ber of metastases with diameter dm(j) (mm).
The main hematological indices were determined 
using the hematological analyzer "Particle counter 
model PCE 210" (ERMA, Japan), adapted for the study 
of blood cells of mice.
The weight and cellularity of spleen, liver and thy-
mus of each tumor-bearing mouse and intact animal 
were examined. The weight index of each organ (WI) 
was calculated using the formula:
WI = 100 • OW/W,
where OW — weight of corresponding organ; W — 
weight of mouse.
For histological analysis paraffin-embedded tis-
sues including thymus, spleen, and liver were sec-
tioned in 5 mm thickness and stained with hematoxylin 
and eosin (H&E) according to a standard procedure 
and examined by light microscopy. Microphotographs 
were done using System Microscope device with 
camera recorder Olympus BX 41 system, supplied with 
digital camera Camedia C-5050 zoom and program 
Olympus DP 80 FT 3.2 at the basis of Pentium 4 with 
operation system Windows XP.
Plasma concentrations of total proteins, albumin, 
total lipids, phospholipids, cholesterol and triglyce-
rides were determined using test kits BioSystems 
(Spain).
Statistical analysis of obtained results included de-
scriptive statistics, Student’s t-test, Mann — Whitney 
u-test was carried out using Statistica v.7.5 program. 
The characteristics of tumor growth and metastasis 
as well as physiological characteristics under study 
were averaged per each group. Mean values and stan-
dard errors were calculated and were used for figure 
and table presentations. The data in Fig. 4, 6, 7 are 
presented as percent of their level in intact mice.
RESULTS AND DISCUSSION
The obtained results showed that ES didn’t stimu-
late LLC/R9 growth. As it seen in Table 1 tumor volume 
in ES treated mice didn’t differ from that in control 
animal during all period of observation.
Table 1. Growth kinetics of LLC/R9 in control and ES treated mice
Day of tumor growth Tumor volume, mm
3
Control mice ES treated mice
8 0 0
10 0.41 ± 0.18 0.5 ± 0.2
13 8.7 ± 2.6 6.9 ± 1.4
15 14.2 ± 3.9 11.0 ± 2.2
17 137.3 ± 30.8 136.8 ± 27.1
21 376.9 ± 59.7 423.2 ± 65.6
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This result has been supported by an analysis 
of histological structure of tumor tissue. By their mi-
croscopic structure the tumors of animals from control 
group and animals treated with ES were similar (Fig. 1). 
In tumor tissue there have been observed the mas-
sive regions with the cells at the state of expressed 
dystrophy and necrobiosis as well as necrotic areas 
what could be related to the large size of the tumors 
in both groups of the animals.
Administration of enterosorbents into the mice 
resulted in inhibition of metastatic process, which 
became apparent in both a tendency to the reduction 
of the number of lung metastases and significant de-
crease of their volume by approximately 50% (p < 0.01) 
as compared to control group (Fig. 2).
a
b
Fig. 1. Murine tumor sections: a — control mice, b — mice 
treated with ES. H&E, × 400
Apart from surface metastases which were counted 
during macroscopic examination of the lungs, on histo-
logical slides of lung tissues of mice from both groups 
there have been detected metastases localized mostly 
close to blood vessels (Fig. 3). Morphological structure 
of lungs of mice from both groups was characterized 
by damaged interalveolar membranes, sometimes 
with their dilacerations and formation of large blebs 
what evidenced on respiratory malfunction. Also, 
in the preparations there were observed large regions 
of hemorrhages where parenchyma was soaked with 
erythrocytes, supposedly due to metastatic process 
in the lungs.
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Fig. 2. Parameters of LLC/R9 growth and metastasis in control 
and ES treated mice. #Difference vs. control mice is statistically 
significant, р < 0.05
a
b
Fig. 3. Murine lung sections: a — control mice, b — mice treated 
with ES. H&E, × 400
In the absence of significant effect toward the 
growth of primary tumor, there has been documented 
an ability of entersorbent to correct the manifestations 
of tumor associated anemia and thrombocytopenia 
in LLC/R9 bearing mice.
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As it was mentioned previously the growth of LLC/
R9 in mice without treatment caused both a statistically 
significant (p < 0.05) decrease of red blood indices 
(including reduction of erythrocyte number on 40% 
and hemoglobin content on 41%) as well as consider-
able fall of platelet number on 47% (p < 0.01) (Table 2, 
Fig. 4).
Table 2. Effect of ES on hematological indices of LLC/R9 bearing mice
Hematologi-
cal indices Units Intact mice
LLC/R9 bearing mice
Control ES treated
RBC 106/μl 10.3 ± 0.2 6.0 ± 0.4* 7.8 ± 0.3*,#
Hgb g/dl 14.3 ± 2.1 8.7 ± 0.6* 10.8 ± 0.7#
Ht % 35.9 ± 1.3 26.9 ± 1.4* 31.5 ± 1.3
MCV fl 42.1 ± 1.9 45.3 ± 2.0 40.4 ± 1.5
MCH pg 12.8 ± 0.4 14.6 ± 0.6 13.8 ± 0.7
MCHC g/dl 30.5 ± 0.4 32.3 ± 0.9 34.0 ± 0.8
RDW % 17.9 ± 0.6 22.7 ± 3.1 18.0 ± 0.7
PLT 103/μl 269.0 ± 34.8 142.6 ± 5.4* 220.3 ± 26.9#
Note: *difference vs. intact animals is statistically significant, р < 0.05; #diffe-
rence vs. control mice is statistically significant, р < 0.05. RBC — erythro-
cyte number; Hgb — hemoglobin content; Ht — hematocrit; MCV — volume 
of erythrocyte; MCH — hemoglobin content in erythrocytes; MCHC — hemo-
globin concentration in erythrocyte; RDW — red blood cell distribution width; 
PLT — platelet number.
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Fig. 4. Effect of ES on erythrocyte, hemoglobin and platelet 
level in blood of LLC/R9 bearing mice in intact mice, control mice 
and ES treated mice. *, #Difference vs. intact and control mice 
(respectively) is statistically significant, р < 0.05
Analysis of peripheral blood showed that ES im-
proved some indices of red blood. In mice treated with 
enterosorbents the erythrocyte number and hemoglo-
bin level were higher by 30.0% (p < 0.05) and 23.3% 
(p < 0.05), respectively, as compared to control mice. 
But these hematological indices remained lower than 
that of intact animal.
In addition administration of enterosorbent com-
pletely normalized the thrombocyte index resulting 
in elevation of pletelet count on 54.5% (p < 0.01) 
up to their level in intact mice (Fig. 4).
Slight changes are observed in leukogram 
of mice after ES treatment (Table 3). In the absence 
of a conside rable influence of LLC/R9 growth 
on leukogram indices oral dosing of sorbent gives rise 
a redistribution of white blood cell composition which 
is characterized by the reduction of monocyte portion 
and an increase of granulocyte one.
Extensive manifestation of the hematological 
PNS in LLC/R9 bearing mice without ES treatment 
is accompanied by formation of extramedullary he-
mopoiesis, which is displayed in hepatomegaly and 
splenomegaly [13].
As it is seen in Table 4 the cellularity and weight 
index of liver in tumor-bearing mice is 60% (p < 0.01) 
higher than these of intact animals.
Table 3. Effect of ES on leukogram indices of LLC/R9 bearing mice
Leukogram 
indices Units Intact mice
LLC/R9 bearing mice
Control ES treated
WBC 103/μl 9.0 ± 0.6 10.9 ± 2.8 8.5 ± 0.5
LY 10
3/μl 6.3 ± 0.4 7.4 ± 1.7 4.7 ± 0.8
% 70.1 ± 0.8 69.0 ± 5.1 53.9 ± 7.3
Mo 10
3/μl 0.98 ± 0.12 1.4 ± 0.4 1.1 ± 0.1
% 10.8 ± 0.8 12.4 ± 1.6 13.2 ± 1.2
Gr 10
3/μl 1.7 ± 0.1 2.1 ± 0.8 2.7 ± 0.5
% 19.1 ± 0.6 18.6 ± 3.6 33.0 ± 7.3*
Note: *difference vs. intact animals is statistically significant, р < 0.05. WBC — 
white blood cells; LY — lymphocytes; Mo — monocytes; Gr — granulocytes.
Table 4. Influence of ES treatment on weight index and cellularity 
of spleen, liver and thymus of LLC/R9 bearing mice
Organ Parameters Units Intact mice LLC/R9 bearing miceControl ES treated
Liver Cellularity 10
6 860.4 ± 63.2 1343.9 ± 96.2* 1405.0 ± 58.1*
Weight index % 3.7 ± 0.4 6.0 ± 0.2* 5.9 ± 0.2*
Spleen Cellularity 10
6 116.4 ± 10.0 238.7 ± 19.2* 228.4 ± 26.8*
Weight index % 0.55 ± 0.06 1.2 ± 0.1* 1.05 ± 0.11*
Thymus Cellularity 10
6 123.0 ± 19.5 25.2 ± 3.2* 32.0 ± 5.7*
Weight index % 0.23 ± 0.03 0.07 ± 0.01* 0.09 ± 0.01*
Note: *difference vs. intact animals is statistically significant (р < 0.05).
In LLC/R9 bearing mice hepatomegaly is accompa-
nied with pathologic changes of morphologic structure 
of liver (Fig. 5, a). 
a
b
Fig. 5. Murine liver sections: a — control mice, b — mice treated 
with ES. H&E, × 400
Normal trabecular structure of the particles is al-
tered, perisinusoidal spaces became widened, the 
signs of anisonucleosis became more expressed: the 
sizes of nuclei ranged from moderate to very large and 
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light, there were observed hepatocytes at the state 
of mitosis. Hepatocytes were mostly low-stained with 
the signs of parenchymatic dystrophy, sometimes 
there were seen nearly transparent cells with cyto-
plasm vacuolarization and pictotic nuclei, and also the 
regions of necrobiosis and necrosis.
These pathologic changes in liver precondition 
malfunction of this organ resulting in the decreased 
levels of the total proteins by 16% (p < 0.05) and serum 
albumin level by 27% (p < 0.05) in blood of tumor-
bearing mice (Fig. 6).
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Fig. 6. Effect of ES on blood protein level in of LLC/R9 bearing 
mice. *, #Difference vs. intact and control mice (respectively) 
is statistically significant, р < 0.05
Against the background of hepatomegaly the level 
of total lipids in the blood plasma of tumor bearing mice 
was six time higher than that of intact animal (Fig. 7, a). 
The concentrations of phospholipids and cholesterol 
were higher on more than 20% (p < 0.05), while the 
concentration of triglycerides was lower on about 20% 
(p < 0.05) in comparison with these indices of intact 
mice (Fig. 7, b).
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Fig. 7. Effect of ES on the level of total lipids (a) and concentra-
tions of phospholipids (PhL), cholesterol (Chol) and triglycerides 
(TrGl) (b) in blood plasma of LLC/R9 bearing mice.*, #Difference 
vs. intact and control mice (respectively) is statistically signifi-
cant, р < 0.05
Despite the fact that after ES there was observed 
no significant alterations in liver weight and cellula rity 
(Table 4), the state of liver parenchyma histological 
structure was significantly better and close to the nor-
mal one. While in a part of liver dystrophic changes still 
remained, the presence of large regions with normal-
ization of morphologic structure has been observed 
(Fig. 5, b). The trabecular structure of hepatocytes 
inside these regions was restored. In the majority of the 
micropreparations hepatocytes preserved their po-
lygonal shape, possessed fine structure of nuclei and 
homogenous cytoplasm staining what may evidence 
on possible normalization of functional activity of liver.
This assumption has been supported by the data 
on the levels of lipids and proteins in blood of mice 
treated with enterosorbent. As it is shown on Fig. 6, 
administration of the sorbent resulted in practically 
complete normalization of the levels of total proteins 
and serum albumin level conditioning the elevation 
of their blood level by 19% (p < 0.05) and 27% (p < 
0.05), respectively.
Administration of enterosorbent also resulted 
in significant decrease of total lipid concentrations 
on 29% (p < 0.01) in blood of treated mice (Fig. 7, a). 
The blood content of phospholipids and triglycerides 
in these animals was shown to be slightly reduced, 
while cholesterol level was 17% lower (p < 0.01) 
in comparison with this index of control mice (Fig. 7, b).
It should be noted that oral dosing of sorbent 
didn’t affect the tumor associated splenomegaly. 
No changes of spleen weight index and cellularity were 
observed in ES treated mice in comparison with that 
of control animal. Meanwhile general morphological 
picture of spleen after ES was much better.
The morphologic picture of spleen in tumor bearing 
mice (in the absence of ES) evidenced on its disturbed 
structure: there were absent distinct margins between 
white and red pulpa as it should be seen at normal state 
(Fig. 8, a). The quantity and area of lymphoid follicles 
(white pulpa) was significantly decreased. Red pulp 
hyperemia was observed along with homogeneity 
of cellular composition and moderate cell density.
After administration of enterosorbent the visual 
ratio between lymphoid nodes and red pulpa was 
notably expressed. The structure of lymphoid follicles 
was homogenous (Fig. 8, b). Some number of follicles 
possessed the distinct germinal centers with blast 
elements and macrophages. In red pulpa there was 
more expressed density of placement of various cel-
lular elements. All mentioned above pointed on some 
normalization of morphologic structure of spleen.
In contrast to the liver and spleen, administration 
of enterosorbent didn’t affect any sign of thymus in-
volution: no changes of weight index, cellularity and 
morphological structure of thymus has been observed 
(Table 4).
Histological examination of the thymus of con-
trol mice and ES treated showed similar morpho-
logical structure. This structure was characterized 
by a sharp shrinkage of the cortical zone, which was 
known for the maturation of the pre-T-thymocytes 
of the bone marrow to T-lymphoblasts and their pro-
liferation (Fig. 9). Medullar zone was characterized 
by a marked reduction of the number of lymphoid 
cells as well as by formation of small cell-free cavities.
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a
b
Fig. 8. Murine spleen sections: a — control mice, b — mice 
treated with ES. H&E, × 400
The results of the study have shown that the 
treatment with carbon microgranulated HSGD 
enterosorbent: 1) didn’t stimulate tumor growth and 
metastasis; 2) decreased the metastatic injury of lung; 
3) corrected the manifestations of paraneoplastic ane-
mia and thrombopenia; 4) improved the morphological 
structure and functional potency of liver.
So, the obtained data denote that ES-based therapy 
can be considered as advanced treatment of cancer 
patients directed on correction of several signs of PNS.
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